Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Fuxe, Kjell ^a   Agnati, L F ^b   Jacobsen, K ^c   Hillion, J ^d   Canals, M ^e   Torvinen, M ^a   Tinner Staines, B ^c   Staines, W ^c   Rosin, D ^f   Terasmaa, A ^a   Popoli, P ^g   Leo, G ^b   Vergoni, V ^a   Lluis, C ^e   Ciruela, F ^e   Franco, R ^e   Ferre S ^h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; DOPAMINE 2 RECEPTOR; METABOTROPIC RECEPTOR 5;

ANIMAL CELL; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; DENDRITIC SPINE; DRUG DEPENDENCE; EMBRYO; FIBROBLAST; GLOBUS PALLIDUS; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRIATE CORTEX;

EID: 10744224952     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095206.44418.5c     Document Type: Article

References (42)

1. Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991;88:7238-7241.
2. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487.
3. 2 receptors in the neostriatum. Brain Res 1992;594:124-130.
4. 2 receptors for dopamine in human striatum. Neuroreport 2001;12:1831-1834.
5. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995;65:709-730.
6. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-346.
7. 2 receptors. J Biol Chem 2002;277:18091-18097.
8. 2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem 2000;74:432-439.
9. 2 receptors in rat neostriatal membranes. Eur J Pharmacol 1993;244:311-315.
10. 2 (long-form) receptor co-transfected mouse fibroblast cell lines: studies on intracellular calcium levels. Neuroscience 1995;68:729-736.
11. Fuxe K, Strömberg I, Popoli P, et al. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 2001;86:345-353.
12. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;8:2694-2706.
13. 2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 2002;44:166-174.
14. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
15. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
16. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
17. 2A adenosine receptors. J Neurosci 2002;22:1054-1062.
18. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res 2001;3:545-556.
19. 2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001;98:1970-1975.
20. Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neuroscience 2000;20:5848-5852.
21. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-2679.
22. 2A) antagonists in PD. Neurology 2002;58:1154-1160.
23. 2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 2001;22:71-72.
24. 2A receptors. Neuroreport 2000;11:3611-3614.
25. 2 receptors in the rat striatum. Neuropharmacology 1999;38:129-140.
26. 2A and glutamate mGluR5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci USA 2002;99:11940-11945.
27. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1-10.
28. Maudsley S, Pierce KL, Zamah M, et al. The β2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000;275:9572-9580.
29. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA 2001;98:2449-2454.
30. 2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells mediate the phosphorylation of extracellular-regulated kinase. Mol Pharmacol 2000;58:477-482.
31. Marinissen MJ, Gurkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001;22:368-376.
32. Hall RA, Premont RT, Lefkowitz RJ. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol 1999;145:927-932.
33. Cho K, Bashir ZI. Cooperation between mglu receptors: a depressing mechanism? Trends Neurosci 2002:25:405-411.
34. Alagarsamy S, Marino MJ, Rouse ST, Gereau RW 4th, Heinemann SF, Conn PJ. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 1999;2:234-240.
35. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002;22:5669-5678.
36. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001;41:413-420.
37. Smith Y, Charara A, Hanson JE, Paquet M, Levey AI. GABA(B) and group I metabotropic glutamate receptors in the striopallidal complex in primates. J Anat 2000;196:555-576.
38. 2A) receptors. Neuropsychopharmacology 2001;25:505-513.
39. 2 receptors. Neurosci Lett 2002;324:154-158.
40. 2A receptors in the rat central nervous system. J Comp Neurol 1998;401:163-186.
41. 1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 2000;97:8606-8611.
42. 1 receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 2002;3:709-719.